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Abstract
Previous studies from our group have shown that the expression levels of Orc6 were highly elevated in colorectal cancer
patient specimens and the induction of Orc6 was associated with 5-fluorouracil (5-FU) treatment. The goal of this study was
to investigate the molecular and cellular impact of Orc6 in colon cancer. In this study, we use HCT116 (wt-p53) and HCT116
(null-p53) colon cancer cell lines as a model system to investigate the impact of Orc6 on cell proliferation, chemosensitivity
and pathways involved with Orc6. We demonstrated that the down regulation of Orc6 sensitizes colon cancer cells to both
5-FU and cisplatin (cis-pt) treatment. Decreased Orc6 expression in HCT-116 (wt-p53) cells by RNA interference triggered cell
cycle arrest at G1 phase. Prolonged inhibition of Orc6 expression resulted in multinucleated cells in HCT-116 (wt-p53) cell
line. Western immunoblot analysis showed that down regulation of Orc6 induced p21 expression in HCT-116 (wt-p53) cells.
The induction of p21 was mediated by increased level of phosphorylated p53 at ser-15. By contrast, there is no elevated
expression of p21 in HCT-116 (null-p53) cells. Orc6 down regulation also increased the expression of DNA damaging repair
protein GADD45b and reduced the expression level of JNK1. Orc6 may be a potential novel target for future anti cancer
therapeutic development in colon cancer.
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Introduction
Orc6 is one of the six origin recognition complex protein in
human cells. It functions as the initial assembly platform that is
required for DNA replication. The roles of Orc6 in DNA
replication have been investigated extensively in both yeast and
Drosophila [1,2,3,4,5,6]. But there are limited information on
human cancer [7,8]. It has been reported that in addition to its
function as a DNA replication initiator protein, it also plays a key
role in transcriptional gene silencing and heterochromatin
formation [8]. However, it is not clear during the initiation
complex assembly at which step that Orc6 participates [9]. It has
been demonstrated elegantly by Prasanth et al. the dynamics of
Orc6 localization during the entire cell cycle, including DNA
replication, chromosome regregation, and cytokinesis. They also
suggest Orc6 may function in signaling to cell cycle control [8].
Our interest in Orc6 stemmed from our previous studies with a
comprehensive genomics analysis revealed that Orc6 is associated
with 5-FU associated resistance in human colon cancer cell lines
[10]. Our follow up study using colorectal patient samples further
confirmed that the expression of Orc6 is highly elevated in human
colorectal tumor tissues compared to paired normal specimens
[11]. These results confirmed the clinical relevance of Orc6
leading to our hypothesis that Orc6 may be a key player that is
involved in colorectal cancer. Its elevated level may also be a
significant contributor to chemoresistance. p53 is one of the most
frequently altered tumor suppressors in colorectal cancer and due
to its critical function in cycle control [12,13]. In this study, we use
a pair of colon cancer cell lines with either wild type p53 or null
p53 as our model system.
In this study, we provide experimental evidence that decreasing
Orc6 expression by RNA interference can sensitize colon cancer
cell lines to two of the major chemotherapeutic agents 5-FU and
cisplatin treatment. Decreasing Orc6 expression by siRNA knock-
down triggered cell cycle arrest and decreased cellular prolifera-
tion in HCT-116 (wt-p53) cells. By contrast, this effect was
significantly impaired in HCT-116 (null-p53) cells. Alteration of
cell cycle control by decreased Orc6 expression was due to the
induction of p21, a major cell cycle control gene. The induction of
p21 was due to the increased the level of phosphorylatd of p53 at
ser-15 triggered by knock-down of Orc6 expression. Orc6 may be
a potential novel target for new anti tumor therapeutic
development.
Results and Discussion
Decreasing Orc6 expression in HCT-116 (wt-p53) cells
inhibits cell proliferation
The increased levels of Orc6 in human colon cancer specimens
led us to investigate the roles of Orc6 in cell cycle control and drug
sensitivity. Using a siRNA knock-down approach, we first
confirmed that the protein levels of Orc6 was decreased using
Western immunoblot analysis in both HCT (wt-p53) cells
(Figure 1A, lane 1, non-specific control siRNA; lane 2, siRNA
against Orc6) and HCT-116 (null-p53) cells (Figure 1A, lane 3,
non-specific control siRNA; lane 4, siRNA against Orc6). The
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e4054expression of Orc6 protein was reduced by more than 5-fold in
HCT (wt-p53) cells and HCT-116 (null-p53) cells.
It has been demonstrated previously that knock-down Orc6 in
Hela cells induced polypoidy [8]. Our results confirmed this in
colon cancer cells, after repeated transfection every 3 days, HCT-
116 (wt-p53) cells with reduced Orc6 expression became
multinucleated (Figure 1B). This population increased with time.
Chromatin was stained with 49,69-diamidino-2-phenylindole
(DAPI) to show multinucleated cells after sustained Orc6
knockdown by siRNA (left panel, light scatter cell image; right
panel, DAPI nuclear staining image in Figure 1B). Cell
proliferation rate was reduced by over 50% (open bar) with
Orc6 knock-down (Figure 2). However, reduction of Orc6
expression in HCT-116 (null-p53) cells reduced in cell prolifera-
tion by only 23% (dashed bar). To investigate the impact of
decreased Orc6 in cell cycle control, HCT-116 (wt-p53) and
HCT-116 (null-p53) cells were first transfected with 100 nM Orc6
siRNA. Transfected cells were exposed to 10 mM 5-FU for 12 hrs.
We observed that 12 hr later, both control HCT-116 (wt-p53) cells
and cells with reduced Orc6 expressing cells were able to remain
largely in the G1 phase without cell cycle re-entry (Figure 3A). By
contrast, HCT-116 (null-p53) control cells and Orc6 reduced cells
were re-entered into S phase of the cell cycle despite the DNA
damage by 5-FU and Orc6 reduction (Figure 3B). These results
suggest that the cell cycle control after DNA damage is depending
on the presence of wild type p53.
Effect of Orc6 on chemosensitivity to 5-FU and cis-pt
To investigate the potential impact of Orc6 on chemosensitivity
to some of the first line chemotherapeutic compounds such as 5-
FU and cis-pt in colorectal cancer, HCT-116 (wt-p53) cells were
used as our model system using cells transfected with oligofecta-
mine alone, non-specific siRNA, and Orc6 specific siRNA. Cells
then treated with 5-FU or cisplatin with serial dilution. After
72 hrs, cell proliferation was quantified by WST-1 assay. Figure 4A
showed that the HCT-116 (wt-p53) cells with reduced Orc6
expression were 5-fold more sensitive to 5-FU treatment compared
to control cells based on IC50 value. HCT-116 (wt-p53) cells with
reduced Orc6 expression were also more sensitive to cisplatin
treatment compared to control cells (Figure 4B). This effect was
largely missing from HCT116 (null-p53) cells (data not show).
Down stream signaling pathways effected by Orc6
To begin to understand the down stream signaling pathways
potentially involved with Orc6, a high throughput gene expression
analysis was used to quantify gene expression changes between
HCT-116 (wt-p53) cells transfected with Orc6 specific siRNA and
non-specific siRNA control. Expression and GeneOntology
analysis showed that a number of genes were influenced by
Orc6 inhibition (Data, S1). Based on our results, a number of well
known cell cycle control genes were confirmed using Western
immunoblot analysis. Our results showed that the expression of
p21 was significantly induced in HCT-116 (wt-p53) cells after
Orc6 knock-down (Figure 5, lane 1, non-specific oligo control;
lane 2, siRNA of Orc6). We further confirmed that the expression
of DNA damage repair protein Gadd45b was also induced by
decreasing Orc6 expression in HCT-116 (wt-p53) cells (Figure 5,
lane 1, non-specific siRNA control; lane 2, Orc6 specific siRNA).
It is well documented that Gadd45b plays an important role in cell
cycle arrest, DNA repair, innate immunity, maintenance of
genome stability and apoptosis [7,14,15,16]. The function of
Gadd45b is mediated through interactions with other proteins
such as cdc2 by disrupting the interaction between ccd2 and cyclin
B1 in triggering G2/M cell cycle arrest under genotoxic stress
[17,18]. Our results showed that Gadd45b is at least, in part,
responsible for the DNA replication defect triggered by reduced
Orc6 expression in colon cancer cells. The expression of JNK1
level was decreased with reduced Orc6 expression (Figure 5). It has
Figure 1. Decreased Orc6 expression by siRNA treatment using
Western Immunoblot analysis in colon cancer cell line HCT116
(wt-p53) (lane 1, non-specific control; lane 2, specific siRNA for
Orc6) and HCT116 (null-p53) cell line (lane 3 non-specific
control; lane 4, specific siRNA for Orc6). a-tubulin was used as
control (A). Increased multinucleation upon silencing of Orc6 in HCT-
116 (wt-p53) cells by siRNA. Left panel, light image; Right panel, DAPI
nuclear staining (B).
doi:10.1371/journal.pone.0004054.g001
Figure 2. Effect of Orc6 on cell proliferation in human colon
cancer HCT-116 (wt-p53) cells (open bar) and HCT116 (null-
p53) cells (dashed bar).
doi:10.1371/journal.pone.0004054.g002
Figure 3. Effect of reduced Orc6 expression in G1/S cell cycle
checkpoint control in both HCT-116 (wt-p53) and HCT (null-
p53) cells by flow cytometry analysis.
doi:10.1371/journal.pone.0004054.g003
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due role in both apoptotic and survival signaling pathways [19,20].
Fibroblasts with JNK knockouts are more sensitive to TNF-
induced apoptosis [21]. Mouse embryo fibroblasts that lack
MKK7 (upstream activator of JNK) undergo cellular senescence
and G2/M growth arrest, further support our finding that reduced
expression of JNK1 may be one of the contributing factors for G2/
M arrest caused by knock-down of Orc6 expression [22]. These
changes were largely absent from the HCT-116 (null-p53) cells
(data not show). This is consistent with previous reported studies
that p53 plays key role in cell cycle control in response to DNA
damage. With the induction of p21 expression, we anticipate that
the subsequent expression of p53 may be increased because p21 is
a known cell cycle check point control gene mediated by p53.
However, the total cellular level of p53 protein was not changed
with the knock-down of p53 expression (Figure 6A, lane 1 and 2).
The induction of p21 was absent in HCT-116 (null-p53) cells with
Orc6 knock-down (Figure 6A, lane 3, control; lane 4, siRNA of
Orc6). This indicates that the induction of p21 expression has to
be p53 dependent despite the absence of in the p53 expression
level. Although the total p53 level did not increase in HCT-116
(wt-p53) cells, we speculate that the level of p53 in the nuclear
fraction may be increased due to known p53 translocation event.
By separating nuclei and cytoplasm, we demonstrated that the
level of total p53 protein in the nuclei was not elevated in HCT-
116 (wt-p53) cells with reduced Orc6 expression treated by Orc6
specific siRNA (Figure 6A). Instead, the level of phosphorylated
p53 at ser-15 was increased in the nuclear fraction of HCT-116
(wt-p53) cells with reduced Orc6 expression (Figure 6B). This is
highly consistent with a well documented mechanism of p53 in
response to DNA damage (14). Phosphorylated p53 at ser-15
Figure 4. Effect of Orc6 expression on cytotoxicity of 5-FU and cis-pt in HCT-116 (wt-p53) cells.
doi:10.1371/journal.pone.0004054.g004
Figure 5. Western immunoblot analysis of cell cycle checkpoint
control genes (p21, Gadd45b, and JNK1) affected by Orc6
knock-down in HCT-116 (wt-p53) cells.
doi:10.1371/journal.pone.0004054.g005
Figure 6. (A) Western immunoblot analysis of p53 and p21 expression
after Orc6 knockdown by siRNA in both HCT-116 (wt-p53) cells (lane 1,
non-specific control; lane 2, specific siRNA for Orc6) and HCT-116 (null-
p53) cells (lane 3, non-specific control; lane 4, specific siRNA for Orc6).
(B) Western immunoblot analysis of phosphorylated p53 expression at
ser-15 in both cytoplasmic and nuclear fraction in control HCT-116 (wt-
p53) cells (lane 1, cytoplasmic; lane 2, nuclear) and HCT-116 (wt-p53)
cells treated with siRNA against Orc6 (lane 3, cytoplasmic; lane 4,
nuclear). Total p53 protein expression levels were used as control
protein in nuclear fractions and a-tubulin was used as control for
cytoplasmic fractions.
doi:10.1371/journal.pone.0004054.g006
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oncoprotein MDM2.
It seems that DNA damage response caused by a decreased Orc6
level is mediated through p53 dependent cell cycle control pathway.
We speculate that high level of Orc6 in colorectal cancer may
contribute to genome instability and perhaps by accumulated miss-
firingofDNAreplicationwithp53deletions/mutationsinover50%
of colorectal tumors. Loss of p53 in colorectal tumors further
contributes to genome instability and accumulated mutations.
Future studies will be needed to fully understand the molecular and
cellular mechanism of Orc6 in colorectal cancer. Despite its
essential role in the initial assembly platform required for DNA
replication, Orc6 may have a potential as an novel target for
anticancer therapeutic development.The situation maybe similar to
26S proteasome as a target for the antibody drug bortezomib.
Initially it was thought that targeting 26S proteasome is not a good
strategy due to its ubiquitous role in protein degradation [23]. Most
recent report from Chen et al. suggests that Orc6 is dispensable in
the DNA binding activity of Orcs in yeast. This further supports our
notion that targeting Orc6 in colorectal cancer is a feasible strategy
for future therapeutic development [24].
In conclusion, we demonstrated, in this study, that down
regulation of Orc6 in colon cancer cells sensitize cells to 5-FU and
cisplatin treatment. Together with our previous studies that Orc6
was highly overexpressed in colorectal cancer patients, we believe
that Orc6 may have potential as a novel anticancer target for
future anti-tumor therapeutic development.
Materials and Methods
Cell Culture
The human colon cancer cell lines, HCT-116 (wt-p53) and
HCT-116 (null-p53) cells were a gift from Professor Bert
Vogelstein (The Johns Hopkins University, Baltimore, MD), and
were maintained in McCoy’s 5A medium (Gibco Laboratories). 5-
FU and cisplatin were purchased from Sigma.
siRNA Transfection
HCT-116 (wt-p53) and HCT-116 (null-p53) were plated in 6-
well trays at 1610
5cells/well and transfected with oligofectamine,
non-specific control siRNA or siRNA against Orc6 at 100 nM
concentration based on the manufacturer’s protocol (Invitrogen
Inc.)
RNA Isolation
Total RNA was isolated from cell lines by using TRIzol reagent
(Invitrogen, San Diego, CA) according to the manufacturer’s
instructions at 24 h after transfection with siRNA.
Western immunoblot analysis
Cells were scraped and lysed in RIPA buffer (Sigma). Equal
amounts of protein samples (50 mg) were resolved by SDS-PAGE
on 12% gels by the method of Laemmli, and transferred to
polyvinylidene fluoride membranes (PVDF) (BIO-RAD Labora-
tories). The membranes were then blocked by 5% nonfat milk in
TBS-T (Tris-buffered saline and 0.5% Tween-20) at room
temperature for 1 h. Proteins were probed with rat anti-orc6
monoclonal antibody (1:1000 dilution, Upstate Technology),
mouse anti-a-tubulin (1:1000 dilution; Santa Cruz Biotechnology,
Santa Cruz,Ca), mouse anti-p53 (1:1000, Santa Cruz) followed by
incubation with a horseradish peroxidase–conjugated secondary
antibody (1:1,000 dilution, Bio-Rad, Hercules, CA). Proteins were
visualized with a chemiluminescence detection system using the
Super Signal substrate (Pierce, Rockford, IL)
Real time qRT-PCR analysis
cDNA synthesis was carried out with the High Capacity cDNA
synthesis kit (Applied Biosystems) using 1 mg of total RNA as
template. The PCR master mix containing TaqMan 26Universal
PCR Master Mix (No Amperase UNG), 106TaqMan assay and
RT products in 25 ml volume were processed as follows: 95uC for
3 min, followed by 40 cycles of 95uC for 15 sec and 60uC for
35 sec (n=3). Signal was collected at the endpoint of every cycle.
The gene expression DCT values of Orc6 from each sample were
calculated by normalizing with internal control GAPDH and
relative quantitation values were plotted.
Cell cycle analysis by flow cytometry
HCT-116 (wt-p53) and HCT-116 (null-p53) were plated in 6-
well trays at 1610
5cells /well and transfected with oligofectamine,
non-specific control siRNA or Orc6 gene specific siRNA at
100 nM concentration. Cells were treated with 5-FU (10 mM)
12 hrs and cells were harvested by trypsin, washed and labeled
with propidium iodide, washed and resuspended in Krisham’s
Modified buffer and filtered for flow cytometry analysis (BD FACS
Caliber).
Supporting Information
Data S1 GeneOntology. Gene Expression and GeneOntology
analysis of differentially expressed genes in control and Orc6
knock-down HCT116 (wt-p53) cells.
Found at: doi:10.1371/journal.pone.0004054.s001 (2.77 MB TIF)
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